A look at a promising drug to control cyst size, growth, and progression to ESRD in ADKPD patients.


Estimated Time to View: 50 minutes
Title: Tolvaptan in the Treatment of Adult Polycystic Kidney Disease: TEMPO 3:4 Trial
Author: Marjan Vandevar, MD
Author Type: Fellow
Citation: Nephrology On-Demand 2013, Volume 4, Number 6
Disclaimers: None
Resource Type: Video
Recommend to a Colleague/Friend: Roll Over
Review this teaching resource: Click here

Pin this resource



To view this 720p high-definition video using an iPad or iPhone, click on the video below
To read the Twitter transcript, click here

Transparent Peer Review

GD Star Rating

To learn more about our 6-point transparent peer review system, click here



  • Nephrology On-Demand Plus

    Our full-featured iOS app for the iPhone and iPad. NOD + integrates
    1. kidney education,
    2. training, and
    3. recruitment

    into a streamlined and user-friendly interface.


  • Kidney Konnection

    A newsletter that discusses sophisticated topics in Nephrology for physicians in Internal Medicine.
    Click here to access your complimentary subscription
More in Cystic Diseases, General Nephrology, Miscellaneous (20 of 224 articles)